HDL Functionality vs. HDL-C

The number on the lipid panel is not the whole job

A standard cholesterol report gives HDL-C in milligrams per deciliter (mg/dL). Many U.S. lab reports flag HDL-C below about 40 mg/dL in men or 50 mg/dL in women as low, and often treat 60 mg/dL or higher as a favorable pattern. That number is useful, but it is easy to overread. HDL-C is not a count of HDL particles. It is not a direct test of how well those particles protect arteries. It is the amount of cholesterol being carried inside high-density lipoprotein particles at the moment blood was drawn.

The surprising part: an HDL particle can be cholesterol-rich and still not be especially effective at its most studied job. Researchers call that job cholesterol efflux capacity, usually shortened to CEC. In plain language, CEC measures how well HDL accepts extra cholesterol from immune cells that have swallowed cholesterol inside artery plaque. This is the first step in moving that cholesterol away from the artery wall and toward disposal by the liver.

Function asks a different question than concentration

HDL-C asks, how much cholesterol is riding in HDL? HDL functionality asks, what can HDL do? The best studied function is cholesterol efflux, but HDL particles also interact with inflammation, oxidation, blood vessel relaxation, and clotting signals. Those other actions are harder to measure consistently, which is one reason HDL functionality has not become a routine clinic test.

This distinction explains a long-standing contradiction. Low HDL-C is associated with higher cardiovascular risk in populations, but medicines that raised HDL-C did not reliably reduce heart attacks when tested as outcomes. Raising the number did not necessarily improve the work. Because of that, recent cholesterol guidance emphasizes lowering plaque-forming particles, especially LDL-C and related measures, rather than treating HDL-C as a target to chase.

What to do when you see your HDL-C

If your HDL-C is low, do not make the day’s decision, “How do I raise HDL?” Make it: check whether your plaque-forming particle burden has been fully assessed. That usually means looking at LDL-C and non-HDL-C on the same lipid panel, and in some people, apolipoprotein B or lipoprotein(a). If your HDL-C is high, do not use it as a permission slip to ignore high LDL-C, high triglycerides, diabetes, smoking, blood pressure, or family history.

For supplements, be especially skeptical of products that promise to “boost good cholesterol” without showing improved outcomes or a meaningful change in plaque-forming particles. Niacin is the classic cautionary example: it can raise HDL-C, but HDL-C movement by itself is not the same as proven cardiovascular benefit. The practical lesson is simple. Treat HDL-C as one clue in the risk picture, not the scorecard.